Catlab Reports Bulletin

The Catlab Reports Bulletin is published monthly. Until the publication of the Catlab website, it was mailed electronically to our clients. It consists of a monograph related with laboratory topics. Each month it addresses a different area of Catlab; the topics can be more specific (concrete diagnostic techniques) or deal with more generic aspects (Quality, Management, …).

Bulletin N 137 - May 2024

Point of care testing (POCT),generalities and challenges of accreditation
Over the last few years POCT tests have emerged as a crucial tool in the field of medical care allowing the obtaining of fast and accurate results, which accelerates the process of diagnosis, follow-up and treatment, thus improving efficiency and the quality of medical care. At Catlab we share our experience in the accreditation of POCT gasometers, through which we demonstrated that the work is done in accordance with internationally accepted standards and that we have the required technical competence.

Bulletin N 136 - April 2024

The use of rapid diagnostic tests are useful for the management of patients with acute pathology who consult in the emergency room,as long as we can change the therapeutic attitude. Indiscriminate use can lead to a misinterpretation of results.
In the ​​microbiology area and paediatrics, we have drawn up a document with indications for use of the Filmarray™ respiratory panel in paediatrics.

Bulletin N 135 - March 2024(II)

Optimization of time and improvement in quality in the genetics service by automating tests with the ELITe InGenius analyzer
Genetics protocols are normally characterized by high complexity and multiple manual processes. Many of these protocols, such as those based on real-time polymerase chain reaction (qPCR), are similar to those used in the Molecular Microbiology section. Taking advantage of the fact that this section made progress in the acquisition of automated equipment due to the SARS-CoV-2 pandemic, the genetics section has proceeded to integrate a part of our activity into this equipment, achieving a substantial improvement in terms of reduction of response times, a reduction in both technical and medical dedication time, lower risk of pre- and post-analytical errors and better traceability of the entire procedure.

Bulletin N 134 - March 2024

ISO 14001
implementation at Catlab. Challenges and opportunities

The climate context in which we find ourselves makes the awareness of all parties to confront it increasingly relevant. Thus, in Catlab, since 2017, an Environmental Management system aligned with the sustainable development objectives began to be implemented, culminating in the ISO14001 Environmental Management certification. During this period, various actions have been carried out, such as the analysis of the carbon footprint and an improvement action plan, aiming at continuous improvement through the application of risk and opportunity matrices reviewed annually.

Bulletin N 133 - February 2024(II)

Informed consent for genetic studies: array-CGH and exome sequencing
Genetic studies available nowadays provide a large amount of information, which can be complex, difficult to understand and assimilate.
In the genetics area of Catlab we have written a complete document, approved by the Healthcare Ethics Committee of the Mutua de Terrassa University Hospital, which contains the necessary information to guide both doctors and patients. This document also contains the consent itself, which must be signed, prior to obtaining the samples and their analysis, by both the patient and the health professional.
This document will be available to all professionals through HCIS, and will be recorded in the patient's medical history.

Bulletin N 132 - February 2024

Antiphospholipid antibodies: detection and clinical relevance
In the laboratory, what classically defines Antiphospholipid Syndrome (APS) is the persistent presence of so-called antiphospholipid antibodies. These constitute a heterogeneous family of autoantibodies that are directed against proteins that intervene in the coagulation cascade and that have an affinity for phospholipids on cell surfaces. Antibodies with the greatest clinical relevance are those included in the laboratory requirements of the APS classification criteria. These antibodies, called classical antiphospholipid antibodies, are anti-cardiolipin and anti-β2-glycoprotein I of isotype IgG and IgM and lupus anticoagulant. In addition to these antibodies included in the classification criteria, antibodies against other phospholipids and cofactors, against specific domains of the cofactors or IgA isotype have also been described. These new antibodies, or non-classical antiphospholipid antibodies, have clinical significance yet to be established and their possible etiopathogenic role is much less known. Below we will review detection and relevance of these antibodies.

Bulletin N. 131 - January 2024

Role of Flow Cytometry in the Study of Lymphoplasmacytic Lymphoma
Flow cytometry represents a key tool for the differential diagnosis of Lymphoplasmacytic Lymphoma (LLP) along with other laboratory techniques since it is often difficult to reach a concrete diagnosis. For this reason in Catlab we have added the CD13 antibody in the CLPD-B study panel and we have made a retrospective internal review of its usefulness for the diagnosis of this entity.

Bulletin N.130 - December 2023

Study of drugs of abuse in urine in the emergency laboratory. Protocol for suspected chemical submission
In Catlab hospital emergency laboratories, drugs of abuse are analyzed in urine using a rapid lateral flow immunochromatographic screening test.
It should be noted that this test provides a qualitative preliminary analytical result and has limitations that are important to be aware of. This article summarizes the main factors that can interact with this test to produce false-positive and false-negative results as well as the cut-off points and detection window for each substance.

Bulletin N.129 - October 2023

High Performance Liquid Chromatography-Mass Spectrometry
Recently, and in collaboration with the Hospital Pharmacy Service of the Hospital
Mutua Terrassa University, a high-efficiency chromatography analytical system in tandem with a mass spectrometry detector (HPLC-MS) has been incorporated into Catlab.
This combination of analytical techniques will allow our laboratory to have,the considered, gold-standard method in clinical laboratory, and thus have the ability to measure analytes with great sensitivity and specificity. The study of immunosuppressants will be the first to make use of this technique and new ones will be added later.

Bulletin Nº128 - September 2023

Changes in the reporting of antibiotic susceptibility in the reporting of
microbiology New interpretation of susceptibility categories S, I and
As of June 2022, the categories used to generate Microbiology culture sensitivity reports in Catlab have been modified in order to include the new recommendations of the European Committee for Antimicrobial Susceptibility Testing (EUCAST).
Thus the less problematic definitions Susceptible(S) and Resistant(R) remain, but the term Intermediate(I) disappears and the term Sensitive: Susceptible to Increased Exposure: S(EI) begins to be used. This new term refers to microorganisms where treatment will increase therapeutic success by increasing antibiotic exposure, dosage or concentration at the site of infection. At Catlab, the Microbiology department remains available to clarify any doubts.